HDAC9 and Miyoshi myopathy: It has previously been shown that daratumumab promotes T-cell expansion, T-cell functional response, and TCR clonality in MM [30], and that HDAC inhibitors can deplete myeloid derived suppressor cells, another potent immunosuppressive cell population favoring tumor immune evasion in the MM microenvironment [34].